3Manzouri B, Vafidis G C, Wyse R K et al. Pharmaeotherapy of Fungal Eye Infections[J]. Expert Opin Pharmacother, 2001,2 (11) : 1849-1857.
4Sunarie M G, Pournaras C J. Current Approach to Postoperative Endophthalmitis[J]. Br. J. Ophthalmol, 1997, 81 (11): 1006-1015.
5Pilar C. Maria J, Alonso J, et al. Improved ocular bioavailahility of inomethacin by novel - ocular drug carries [J]. J Pharm Pharmacol, 1997, 49 (8) : 737 - 742.
6Zimmerman TJ, Kooner KS, Sharir M, et al. Textbook of Ocular Pharmaco logy [M]. New York: Lippincott -Raevn Pubisbers, 1997:119 - 138.
7Giunchedi P, Conte U. Dectin microspheres as ophthalmic carries for piroxicam evaluation in vitro and in viva in albino rabbits[J]. Eur J Pharma Sci, 1999(9): 1 -7.
8Srividya B, A min PD, Cardoza RM. Sustained ophthalmic delivery of loxacin from a PH triggered in situ gelling system[J ]. J Contro Rel, 2001, 93(2 -3): 205 -211.
9AM De Campos, A Sanchez, MJ Alonso. Chitosam nanoparticles: a new vehicle for the improvement of delivey of drugs to ocular surface. Application to cyclosporin A[J]. inter J Pharm, 2001,224:145 - 168.
10Zimmer A, Kkreuter J. Microapheres and nanoparticles used in ocular delivery systems [ J ]. Adv Drug Deliv Rev, 1995, 16 ( 1 ) : 61 - 73.
